Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's lead product candidates are roluperidone (MIN-101) and MIN-301. Roluperidone (MIN-101) is a compound that blocks serotonin, sigma, and α adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. The Company is developing roluperidone to treat patients with schizophrenia. Roluperidone is designed to block a specific subtype of serotonin receptor called 5-HT2A. The Company’s MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson’s disease and for other neurodegenerative disorders. The Company is also developing seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD).